Sanofi
SNY
474 hedge funds and large institutions have $11.3B invested in Sanofi in 2017 Q2 according to their latest regulatory filings, with 53 funds opening new positions, 127 increasing their positions, 187 reducing their positions, and 29 closing their positions.
710% more call options, than puts
Call options by funds: $88.5M | Put options by funds: $10.9M
83% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 29
4% more funds holding
Funds holding: 454 → 474 (+20)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
0% less capital invested
Capital invested by funds: $11.4B → $11.3B (-$33.8M)
0.67% less ownership
Funds ownership: 19.33% → 18.66% (-0.67%)
32% less repeat investments, than reductions
Existing positions increased: 127 | Existing positions reduced: 187
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$70.1M |
| 2 |
SCA
Southpoint Capital Advisors
New York
|
+$57.3M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$48.9M |
| 4 |
BlackRock
New York
|
+$34.4M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$28.3M |
Top Sellers
SNY Hedge Fund Activity: Q2 2017 in Review
474 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Sanofi (SNY) for Q2 2017, worth a combined $11.3B — down 0.3% from $11.4B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new SNY positions and 29 closed out — a net gain of 24 holders — while 127 added to existing stakes and 187 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $70.1M. The largest seller was Dodge & Cox, cutting an estimated $253M.
- 474 institutional investors held Sanofi (SNY) as of Q2 2017, up from 454 in Q1 2017.
- Funds reported $11.3B of Sanofi stock for Q2 2017, down 0.3% quarter-over-quarter.
- 53 funds opened new Sanofi positions in Q2 2017 and 29 closed out, a net change of +24 holders.
- The largest Sanofi buyer in Q2 2017 was Morgan Stanley, an estimated $70.1M added.
- The largest Sanofi seller in Q2 2017 was Dodge & Cox, an estimated $253M sold.
Based on aggregated 13F filings for Q2 2017.